|Print Page | Close Window|
2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.View our latest Annual Report
See stock & dividend information
Baxter International Inc.
NYSE: BAXMar 23, 2018 - 4:00 PM ET
03/13/2018 10:15 AM ET
03/06/2018 4:35 PM ET
02/21/2018 10:30 AM ET
02/14/2018 11:30 AM ET
Baxter Completes Acquisition of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio
Investor relations contact
Analysts, portfolio managers, and current and prospective shareholders seeking additional investor information can contact Clare Trachtman at +1 (224) 948-3085.
Retail shareholder inquires may directed to Baxter Investor Relations at Global_CORP_Investor_Relations@baxter.com.Sign up for email alerts